NBDF/LinkedIn
Sep 11, 2025, 13:37
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
National Bleeding Disorders Foundation shared on LinkedIn:
”Promising news for the hemophilia community!
Pfizer’s HYMPAVZI™ (marstacimab-hncq) shows a 93% reduction in treated bleeds in its Phase 3 trial for people with hemophilia A or B with inhibitors.”
Learn more here.
Stay updated on the emerging in the field of hemophilia with Hemostasis Today.
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke